Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene Expression Profiling of Mismatch Repair Deficient Intestinal Stem Cells

ABSTRACT: Gene Expression Profiling of Mismatch Repair Deficient Intestinal Stem Cells

PROVIDER: PRJNA642180 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12099960_1.fastq.gz	Fastqsanger.gz
	SRR12099960_2.fastq.gz	Fastqsanger.gz
	SRR12099961_1.fastq.gz	Fastqsanger.gz
	SRR12099961_2.fastq.gz	Fastqsanger.gz
	SRR12099962_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 555

Similar Datasets

Gene Expression Profiling of Mismatch Repair Deficient Intestinal Stem Cells

Project description:We have generated a gene signature of mismatch repair (MMR) deficient intestinal stem cells (ISCs) using whole-genome transcriptomics and proteomics from murine intestinal stem cells and epithelial non-stem cells in a Lynch syndrome mouse model (Msh2-fl/fl;Villin-Cre). Then we have validated this signature in RNA-seq data from LS normal unaffected mucosa (UM), adenomas (AD) and adenomas with high-grade dsyplasia (AD-HGD) and tumors (T). MMR status for LS tumors and adenomas with high-grade dysplasia was categorized as KO, for unaffected mucosa as HET and FAP samples as WT.

2021-06-01 | GSE153385 | GEO

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Project description:This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient tumors (dMMR) may have difficulty repairing DNA mutations during replication that may affect tumor’s response to therapy. Immunotherapy with monoclonal antibodies, such as tislelizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tislelizumab may help treat patients with mismatch repair deficient endometrial cancer.

| 2379033 | ecrin-mdr-crc

Novel Mechanisms of Antibiotic Resistance in Mismatch Repair-Deficient Pseudomonas aeruginosa hypermutators

Project description:Using in vitro directed evolution, we show that mismatch repair-deficient Pseudomonas aeruginosa can engage novel resistance mechanisms to ceftazidime-avibactam.

2021-08-30 | GSE180086 | GEO

Cisplatin-induced gene expression in DNA adenine methyltransferase (dam) and mismatch repair deficient E. coli

Project description:We used Affymetrix microarrays to determine the cisplatin-induced gene expression changes in E. coli deficient in dam and mismatch repair (dam, dam mutS, and mutS mutant strains). E. coli deficient in dam are hypersensitive to cisplatin. However introducing an additional mutation in mismatch repair (i.e., a mutation in mutS or mutL) abrogates this sensitivity and essentially restores wildtype levels of resistance. Keywords: Drug-induced expression

2005-07-27 | GSE2999 | GEO

Rhesus Macaque Model of Mismatch Repair-Deficient Colorectal Cancer

Project description:Rhesus Macaque Model of Mismatch Repair-Deficient Colorectal Cancer

| PRJNA738804 | ENA

Transcription profiling of three human colorectal adenocarcinoma cells lines two which are mismatch repair deficient to characterize the post-transcriptional profile

Project description:characterize the post-transcriptional profile of mismatch repair-deficient colon cancer

2008-07-15 | E-MEXP-1696 | biostudies-arrayexpress

GENOMIC INSTABILITY IN MISMATCH REPAIR DEFICIENT COLORECTAL CANCER

Project description:Here we performed whole exome sequencing on a series of 47 mismatch repair (MMR) deficient colorectal cancers (CRC) in order to identified key events in tumoral initiation and progression

| EGAS00001002477 | EGA

Rhesus Macaque Model of Mismatch Repair-Deficient Colorectal Cancer (RRBS)

Project description:Rhesus Macaque Model of Mismatch Repair-Deficient Colorectal Cancer (RRBS)

| PRJNA738802 | ENA

Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

Project description:This randomized phase Ib trial studies the side effects and best dose of naproxen in preventing deoxyribonucleic acid (DNA) mismatch repair deficient colorectal cancer in patients with Lynch syndrome. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of naproxen may keep cancer from forming in patients with Lynch syndrome.

| 2160055 | ecrin-mdr-crc

Rhesus Macaque Model of Mismatch Repair-Deficient Colorectal Cancer (RNA-Seq)

Project description:Rhesus Macaque Model of Mismatch Repair-Deficient Colorectal Cancer (RNA-Seq)

| PRJNA738813 | ENA